HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

BACKGROUND: Trastuzumab emtansine (T-DM1) is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), and has high efficacy. However, some patients exhibit primary resistance to T-DM1, and thus methods that can predict resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Hitomi, Tsurutani, Junji, Iwasa, Tsutomu, Komoike, Yoshifumi, Sakai, Kazuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132843/
https://www.ncbi.nlm.nih.gov/pubmed/29700710
http://dx.doi.org/10.1007/s12282-018-0861-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132843/
https://www.ncbi.nlm.nih.gov/pubmed/29700710
http://dx.doi.org/10.1007/s12282-018-0861-9

Ejemplares similares